Whitaker Lucy H R, Reid Jen, Choa Alex, McFee Stuart, Seretny Marta, Wilson John, Elton Rob A, Vincent Katy, Horne Andrew W
MRC Centre for Reproductive Health, University of Edinburgh, The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, United Kingdom.
The University of Edinburgh Medical School, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom.
PLoS One. 2016 Apr 5;11(4):e0151950. doi: 10.1371/journal.pone.0151950. eCollection 2016.
Chronic pelvic pain (CPP) affects 5.7-26.6% women worldwide. 55% have no obvious pathology and 40% have associated endometriosis. Neuropathic pain (NeP) is pain arising as a consequence of a lesion/disease affecting the somatosensory system. The prevalence of NeP in women with CPP is not known. The diagnosis of NeP is challenging because there is no gold-standard assessment. Questionnaires have been used in the clinical setting to diagnose NeP in other chronic pain conditions and quantitative sensory testing (QST) has been used in a research setting to identify abnormal sensory function. We aimed to determine if women with chronic pelvic pain (CPP) have a neuropathic pain (NeP) component to their painful symptoms and how this is best assessed. We performed an exploratory prospective cohort study of 72 pre-menopausal women with a diagnosis of CPP. They underwent a clinician completed questionnaire (DN4) and completed the S-LANSS and PainDETECT™ questionnaires. Additionally QST testing was performed by a clinician. They also completed a patient acceptability questionnaire. Clinical features of NeP were identified by both questionnaires and QST. Of the women who were NeP positive, 56%, 35% and 26% were identified by the S-LANSS, DN4 and PainDETECT™ respectively. When NeP was identified by questionnaire, the associated laparoscopy findings were similar irrespective of which questionnaire was used. No subject had entirely unchanged QST parameters. There were distinct loss and gain subgroups, as well as mixed alteration in function, but this was not necessarily clinically significant in all patients. 80% of patients were confident that questionnaires could diagnose NeP, and 90% found them easy to complete. Early identification of NeP in women with CPP with a simple questionnaire could facilitate targeted therapy with neuromodulators, which are cheap, readily available, and have good safety profiles. This approach could prevent unnecessary or fertility-compromising surgery and prolonged treatment with hormones.
慢性盆腔疼痛(CPP)影响着全球5.7%-26.6%的女性。55%的患者无明显病理改变,40%的患者伴有子宫内膜异位症。神经性疼痛(NeP)是由影响躯体感觉系统的病变/疾病引起的疼痛。CPP女性中NeP的患病率尚不清楚。NeP的诊断具有挑战性,因为没有金标准评估方法。问卷调查已用于临床诊断其他慢性疼痛疾病中的NeP,定量感觉测试(QST)已用于研究环境中以识别异常感觉功能。我们旨在确定慢性盆腔疼痛(CPP)女性的疼痛症状中是否存在神经性疼痛(NeP)成分以及如何进行最佳评估。我们对72名诊断为CPP的绝经前女性进行了一项探索性前瞻性队列研究。她们接受了临床医生完成的问卷(DN4),并完成了S-LANSS和PainDETECT™问卷。此外,临床医生进行了QST测试。她们还完成了一份患者可接受性问卷。通过问卷和QST确定NeP的临床特征。在NeP阳性的女性中,分别有56%、35%和26%通过S-LANSS、DN4和PainDETECT™确定。当通过问卷确定NeP时,无论使用哪种问卷,相关的腹腔镜检查结果相似。没有受试者的QST参数完全不变。存在明显的功能丧失和增强亚组,以及功能的混合改变,但这在所有患者中不一定具有临床意义。80%的患者相信问卷可以诊断NeP,90%的患者认为问卷易于完成。通过简单问卷早期识别CPP女性中的NeP可以促进使用神经调节剂进行靶向治疗,神经调节剂价格便宜、容易获得且安全性良好。这种方法可以避免不必要的或影响生育的手术以及长期激素治疗。